# AffyImmune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affyimmune-therapeutics

- Industry: Biotechnology
- Headquarters: Natick, US
- Website: www.affyimmune.com
- Total disclosed funding: $30M
- Latest round: Series A (Oct 7, 2021)
- Investors on record: 1

## About

AffyImmune Therapeutics Inc. focuses on developing innovative cellular therapies that leverage the patient's immune system to target tumor cells overexpressing ICAM-1, with an emphasis on treating advanced thyroid cancers.Founded in 2016 and based in Natick, US, AffyImmune Therapeutics Inc. specializes in immunotherapy. The firm has raised a total of USD 30.00 mn in its Series A funding round led by ORI Capital on October 7, 2021, with a focus on developing ICAM-1-directed therapies. Founders Gang Song and Moonsoo Jin have a history of involvement in innovative healthcare solutions.AffyImmune Therapeutics, Inc. specializes in developing advanced cellular therapies that utilize the patient’s immune system to target and eliminate tumor cells characterized by the overexpression of ICAM-1. Their primary product, AIC100, is an ICAM-1-directed CAR T therapy aimed specifically at patients suffering from anaplastic and advanced differentiated thyroid cancers. The innovative technology enhances CAR T cell affinity, allowing for the selective destruction of tumor cells while preserving healthy tissue. The company also ensures non-invasive monitoring of engineered CAR T cells during treatment, addressing significant unmet medical needs in oncology, particularly in North America and Europe.AffyImmune Therapeutics, Inc. has a revenue model that relies on partnerships and collaborations with healthcare providers and research institutions. These agreements typically involve the provision of CAR T cell therapies, especially AIC100, to oncologists and hospitals treating advanced thyroid cancers. Revenue is generated through research funding, licensing agreements, and milestone payments linked to the clinical development and commercialization of their therapies, reflecting the innovative nature of their solutions.AffyImmune Therapeutics Inc. is utilizing the USD 30.00 mn raised in Series A funding to further advance the Phase 1 study of AIC1000, which is targeted for treating anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer. The company aims to expand its therapeutic offerings and improve patient outcomes through innovative products, while also exploring new markets for their therapies in regions with high incidences of thyroid cancer. Plans include strategic collaborations and research initiatives to facilitate this growth.

## Funding rounds

- Series A, Oct 7, 2021, $30M — ORI Capital

## Investors

- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series A